Biotech & Genomic Medicine▲
mRNA Cancer Vaccine Market to Surpass $1.20 Billion in 2026, Report Finds
The global mRNA cancer vaccine market is projected to exceed US$1.20 billion by 2026, according to a new report from ResearchAndMarkets.com. The market is expected to see continued robust growth through 2036, driven by advances in precision oncology, sequencing technologies, and an expanding pipeline of clinical candidates. Key players such as BioNTech, Moderna, Arcturus Therapeutics, and Sana Biotechnology are advancing platform and clinical innovations, while innovations like self-amplifying mRNA constructs and improved lipid nanoparticle delivery systems are enhancing scalability. The report also highlights that production relies on globally sourced inputs like lipid nanoparticles and nucleotides, making supply chains vulnerable to tariffs and disruptions, which could impact costs and development timelines. The analysis covers market segmentation by vaccine type, therapeutic approach, clinical phase, indication, and end-user across regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.